AR106198A1 - Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3) - Google Patents

Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3)

Info

Publication number
AR106198A1
AR106198A1 ARP160102983A ARP160102983A AR106198A1 AR 106198 A1 AR106198 A1 AR 106198A1 AR P160102983 A ARP160102983 A AR P160102983A AR P160102983 A ARP160102983 A AR P160102983A AR 106198 A1 AR106198 A1 AR 106198A1
Authority
AR
Argentina
Prior art keywords
tim3
bispecific antibodies
cell death
programmed cell
immunoglobulin superfamily
Prior art date
Application number
ARP160102983A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR106198A1 publication Critical patent/AR106198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación se refiere a anticuerpos biespecíficos que comprenden un primer sitio de unión a antígeno que se une específicamente a PD1 y un segundo sitio de unión a antígeno que se une específicamente a TIM3, en particular a anticuerpos biespecíficos, en el que el anticuerpo biespecífico se une a TIM3 con una afinidad menor en comparación con la unión a PD1. La divulgación se refiere además a métodos para producir estas moléculas y a métodos para usar las mismas, en prevención o tratamiento del cáncer.
ARP160102983A 2015-10-02 2016-09-29 Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3) AR106198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15188036 2015-10-02

Publications (1)

Publication Number Publication Date
AR106198A1 true AR106198A1 (es) 2017-12-20

Family

ID=54256606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102983A AR106198A1 (es) 2015-10-02 2016-09-29 Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3)

Country Status (1)

Country Link
AR (1) AR106198A1 (es)

Similar Documents

Publication Publication Date Title
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
ECSP19078429A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
CL2018001326A1 (es) Proteínas de unión a ctla4.
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
MY200602A (en) Antibodies against tim3 and uses thereof
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
AR106555A1 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
PE20180499A1 (es) Anticuerpos de union a tau
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
ECSP19078414A (es) Anticuerpos anti-cd33 y métodos para utilizarlos
PE20190737A1 (es) Anticuerpos anti-cd27
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9